Key result
MicroRNA-145 exerts context-dependent dual regulatory effects across cardiovascular diseases, emerging as a potential therapeutic target.
Why the study?
MicroRNA-145 exerts dual context-dependent effects in cardiovascular diseases, and its therapeutic application is constrained by poor in vivo stability, rapid ribonuclease degradation, and low transfection efficiency. Furthermore, unresolved controversies and unanswered scientific questions remain regarding its regulatory mechanisms, delivery technologies, and clinical translation.
Answers are grounded in this paper and cite their sources.
This narrative review highlights the cell- and microenvironment-dependent dual regulatory roles of miR-145 across various cardiovascular diseases, emphasizing the necessity for cell-specific targeted delivery systems to harness its diagnostic and therapeutic potential safely.
MicroRNA‑145 (miR‑145) is a non‑coding RNA involved in vascular remodeling, myocardial injury and fibrosis, and it contributes to the onset and progression of several cardiovascular disorders. Accumulating evidence indicates that the functions of miR‑145 depend on cell subtypes and pathological microenvironments. miR‑145 exerts dual regulatory effects in atherosclerosis, myocardial ischemia‑reperfusion injury, hypertension, pulmonary arterial hypertension ventricular remodeling and heart failure. In some settings, for example in cardiomyocytes subjected to myocardial ischemia‑reperfusion injury (MIRI), miR‑145 can suppress disease progression and protect the myocardium and vasculature; conversely, it may trigger tissue injury and exacerbate disease in specific cell types and pathological setting; for example, in cardiac microvascular endothelial cells during MIRI. Abnormal expression of miR‑145 is associated with disease severity, risk stratification and the incidence of long‑term adverse cardiovascular events, suggesting its potential as a molecular biomarker for early screening, disease assessment and prognosis of cardiovascular diseases (CVDs). Unconjugated or unformulated miR is limited by poor in vivo stability, rapid degradation by ribonucleases and low cellular transfection efficiency. To address these limitations, three major delivery platforms, namely extracellular vesicles, viral vectors and nanoparticles, have been developed for targeted delivery of miR‑145 and these platforms differ in biosafety, delivery efficacy and modifiability. As research advances in nucleic acid‑based targeted therapeutics, several miR‑based agents have entered clinical trials, supporting the development of targeted interventions for CVDs. The present review examined the dual regulatory mechanisms, potential clinical applications and current delivery technologies of miR‑145 across CVDs. The translational progress and limitations of current miR therapeutics were reviewed, as well as unresolved controversies and unanswered scientific questions. The present work aimed to inform further mechanistic studies of miR‑145 and the research, development and clinical translation of cardiovascular nucleic acid‑targeted therapies.
No takes yet. Share an insight, caveat, or question.
Jian et al. (2026) conducted a review in Cardiovascular diseases (atherosclerosis, myocardial ischemia-reperfusion injury, heart failure, pulmonary arterial hypertension, and hypertension). microRNA-145 (miR-145) was evaluated. MicroRNA-145 exerts cell-subtype and microenvironment-dependent dual regulatory effects across cardiovascular diseases and serves as a potential biomarker and therapeutic target.
Synapse has enriched 10 related papers. Consider them for comparative context: